Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Sponsor: Janssen Research & Development, LLC
Listed as NCT00887198, this PHASE3 trial focuses on Prostate Cancer and remains completed. Sponsored by Janssen Research & Development, LLC, it has been updated 11 times since 2009, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Mar 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Mar 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Jul 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Oct 2017 — Feb 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Apr 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Research & Development, LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Aachen, Germany , Aalst, Belgium , Adelaide, Australia , Amsterdam, Netherlands , Antwerp, Belgium , Athens, Greece , Atlanta, United States , Aurora, United States , Baltimore, United States and 124 more locations